Pregnancy-associated deaths due to overdoses have significantly increased over the past decade, and there has been a progressive increase in pregnancy-associated mortality due to psychostimulants and synthetic opioids including fentanyl. A study on pregnancy-associated deaths from 2017-2020 revealed that 16.3% of these deaths were overdose related and associated with a mortality rate of 8.35 per 100,000 [1]. Pregnancy-associated overdose mortality gradually increased over the study period, with increases in overdose mortality in 2020 being more pronounced than increases in any previous year [1].For countless women with substance use disorders, the ED is the first point of care. Clinicians play a key role in impacting outcomes in this maternal health crisis [2]. There are several factors that contribute to the increase in pregnancy-associated overdoses including disparities that lead to challenges in accessing drug treatment services and difficulties in achieving timely harm reduction [1]. These disparities disproportionately affect BIPOC and have persisted despite advancements in medical care [3]. Treatment strategies require a multidisciplinary coordinated approach that focuses on not only the mother but also the infant.In our talk, we will discuss time-sensitive ways through which clinicians can address pregnancy-associated overdose mortality in the EP setting. We will discuss the importance of early universal screening, brief interventions, counseling and education in the ED, and referral to support services [4]. We will also discuss identifying withdrawal symptoms in the mother and infant, pain control strategies, and modifying elements of prenatal care for women with OUD.
Learning Objectives:- Understand trends in pregnancy-associated overdose deaths.
- Learn time-sensitive ways to help clinicians address pregnancy-associated overdose mortality in the EP setting.
- Learn how to modify elements of prenatal care to best care for women with OUD in the prenatal and post-partum period.